[Initial clinical results using new, experimentally developed therapeutic forms in leprosy].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000494:pharmacology; D002648:Child; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005002:Ethiopia; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000187:drug effects; D012293:Rifampin / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects; D013449:Sulfonamides / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use; D013997:Time Factors; D014295:Trimethoprim / Q000627:therapeutic use
D000995:Antitubercular Agents; D013449:Sulfonamides; D013792:Thalidomide; D003622:Dapsone; D014295:Trimethoprim; D012293:Rifampin
Erste klinische Ergebnisse mit neuen, experimentell entwickelten Therapieformen bei der Lepra.